Ensuring that patients can continue to benefit from safe medicines requires innovative approaches to expose and outwit counterfeiters. Lilly has made a sustained, long-term commitment to address this challenging problem. Our efforts include:
- Securing the integrity of Lilly products through the legitimate supply channels.
- Deterring major counterfeiters of Lilly products through targeted investigations, Internet monitoring and legal actions.
- Partnering with government, non-government organizations and trade associations to strengthen, enact and enforce anti-counterfeiting laws and raise awareness.
Patient safety is the driving force behind Lilly’s global anti-counterfeiting efforts. Lilly is deeply engaged in efforts to combat counterfeiters. We are a founder and board member of the Alliance for Safe Online Pharmacies (ASOP), a broad coalition of stakeholders with an interest in protecting patient safety and ensuring patients have access to safe and legitimate online pharmacies. In Europe, we are an active partner in the European Alliance for Access to Safe Medicines (EAASM) and ASOP EU to further patient education about the dangers of counterfeit medicine.
Lilly is working collaboratively with European stakeholders (pharmacists, wholesalers and parallel distributors) on the successful implementation of the Falsified Medicines Directive to help ensure counterfeit medicines cannot be dispensed to patients through legitimate supply chain channels in the EU.
In the U.S., Lilly has been involved in advocating for federal legislation that will help to protect patients from counterfeit drugs. One of Lilly’s major legislative efforts has been to advocate for the establishment of a uniform federal standard for coding, serializing and tracking pharmaceutical products.
Lilly also supports the Online Pharmacy Safety Act, which would update U.S. law to protect patients from the growing number of illegitimate and unsafe online drug sellers. Lilly also supports the National Association of Boards of Pharmacy (NABP) as it plans to launch the “.pharmacy” top-level domain name as a home for safe and legal online pharmacies.
In addition, Lilly supports law enforcement in the criminal prosecution of counterfeiters around the world, through gathering evidence, testing samples, testifying in court, and filing civil actions. Lilly also participates in the World Customs Organization’s IPM database of products, used by customs agents to identify legitimate versus counterfeit products that cross national borders.
To stop counterfeit medicines, we must combine the efforts of governments, patient organizations, medical networks, manufacturers (brand owners) and others. We will succeed in stopping this threat only if we act together – and act globally.